Research progress regarding the role of long non-coding RNAs in osteosarcoma (Review)

YANLI ZHANG*, YANCHUAN PU*, JIN WANG, ZICAI LI and HULIN WANG

Department of Orthopedics, Wuwei People's Hospital, Wuwei, Gansu 733000, P.R. China

Received February 11, 2020; Accepted May 29, 2020

DOI: 10.3892/ol.2020.11807

Abstract. Osteosarcoma is a malignant tumor that occurs in children and adolescents. Although treatments for osteosarcoma have improved, the likelihood of survival remains low for most patients with metastasis and recurrence. Elucidating the mechanism underlying the development of osteosarcoma and chemotherapy resistance will be important to improve diagnosis and treatment. Long non-coding RNAs (lncRNAs), which are longer than 200 nucleotides in length and do not encode for proteins, have been shown to play a regulatory role in the occurrence and development of osteosarcoma, and are expected to serve as biomarkers and molecular targets. This review discusses the progress in the study of the role of lncRNAs in osteosarcoma, and highlights the recent developments in this field.

Contents

1. Introduction
2. Classification and biological function of lncRNAs
3. Promotive role of lncRNAs in the occurrence and development of OS
4. Inhibitory effect of lncRNAs on the development of OS
5. The role of lncRNAs in OS resistance
6. Summary and prospects

1. Introduction

Osteosarcoma (OS) is a malignant tumor that accounted for 15% of all diagnosed malignancies in children and adolescents in 2015 that seriously affects the health of these groups of individuals worldwide (1). Epidemiological statistics show that the survival rate of patients with primary OS is only 65-70% and the survival rate after metastasis is only 19-30%; thus, current clinical treatments do not effectively cure OS (2,3). Currently, >90% of patients with OS are treated with limb-preserving surgeries (3). However, the high rates of recurrence, metastasis, and mortality of spinal OS result in an extremely low 5-year survival rate (3). Therefore, identifying novel biomarkers involved in the pathogenesis of OS is of great significance.

Long non-coding RNAs (lncRNAs) are functionally defined as gene transcripts more than 200 nucleotides in length that have no protein-encoding potential. lncRNAs act as major regulatory RNAs, that regulate gene expression at the epigenetic or genetic level. In particular, lncRNAs have been found to play an important role in the occurrence, development and angiogenesis of tumors (4). With the development of next-generation sequencing technology, the OS-associated mutation spectrum has been deciphered, including the expression profiles of lncRNAs. A large number of lncRNAs have been found to play an important role in the occurrence, development and drug resistance in OS (5,6). Further studies on the role of lncRNAs in OS will improve the understanding and ability to treat this disease. This review summarizes current knowledge regarding the function of lncRNAs at the molecular level and the implications for OS research and therapy.

2. Classification and biological function of lncRNAs

lncRNAs are classified as sense lncRNAs, antisense lncRNAs, bidirectional lncRNAs, intron lncRNAs, intergenic lncRNAs, or enhancer lncRNAs, according to the positional association between lncRNAs and protein-coding genes in the genome (7).

At present, the regulation of genes by lncRNAs mainly occurs at the transcriptional and post-transcriptional levels (8). lncRNAs can regulate gene expression through chromatin modification, remodeling, histone modification and nuclear body localization (9). In cooperation with the SWI/SNF complex, lncRNAs can also change the structure of chromosomes, thus directly affecting gene expression (10). lncRNAs can directly induce DNA methylation and damage, which can also affect gene expression (11,12). Finally, lncRNAs can regulate gene expression through complex interactions with microRNAs (miRNAs) (13) (Fig. 1).
3. Promotive role of lncRNAs in the occurrence and development of OS

The occurrence and development of OS is a complex process involving many factors. While the molecular mechanisms of these physiological and biological processes have not been fully elucidated, it is clear that lncRNAs play an important role (5,6,14).

lncRNAs directly promote the occurrence and development of OS. Dong et al (15) revealed that the upregulation of bladder cancer associated transcript 1 (BLACAT1) predicted an unfavorable prognosis for patients with OS. The downregulation of BLACAT1 inhibited cell proliferation and invasion, whereas the upregulation of BLACAT1 accelerated cell proliferation and invasion. More importantly, BLACAT1 accelerated the proliferation and migration of OS cells by regulating the phosphorylation of STAT3. Zhao et al (16) showed that HLA complex P5 (HCPS5) acts as an oncogene in OS, and the upregulation of HCPS5 promoted cell proliferation and invasion, the epithelial-mesenchymal transition (EMT), and the development of OS. Chen et al (17) showed that LOXL1 antisense RNA 1 (AS1) predicted the clinical progression and poor prognosis in patients with OS, and functions as an oncogenic lncRNA, regulating cell proliferation, cell cycle, migration, and invasion via the PI3K/AKT pathway. Su et al (18), revealed that ELK1-induced upregulation of MIR100HG predicted poor prognosis and promoted the progression of OS by epigenetically silencing large tumor suppressor kinase (LATS)1 and LATS2, and inactivating the Hippo pathway. Another study suggested that the lncRNA hepatocellular carcinoma upregulated lncRNA could promote the occurrence of bone tumors by enhancing the proliferation, invasion, migration and expression of EMT-associated factors of OS (19). Meanwhile, nuclear paraspeckle assembly transcript 1 was shown to be significantly upregulated in OS tissue, indicating that it could effectively promote the proliferation and metastasis of OS cells (20). Meanwhile, Gu et al (21) confirmed that HOXD-AS1 could interact with enhancer of zeste homolog 2 (EZH2), thereby decreasing the expression of p57 and exacerbating OS. Yang et al (22), found that upregulated forkhead box P4-AS1 promoted OS proliferation, migration and the cell cycle, but inhibited apoptosis; this effect was achieved through the interaction with lysine-specific demethylase 1 and EZH2, and further downregulation of LATS1. Yu et al (23), demonstrated that antisense non-coding RNA in the INK4 locus (ANRIL) affects OS cell proliferation, invasion and apoptosis by regulating the AKT pathway. Ye et al (24), found that nctinamide nucleotide transhydrogenase (NNT)-AS1 could inhibit the proliferation, migration and invasion of OS cells, as well as tumor growth, by inhibiting the expression of NNT-AS1. Zhang et al (25), also demonstrated that prostate cancer-associated transcript 1 could promote cell proliferation, invasion and migration, as well as the EMT, in OS. Li et al (26), showed that colorectal neoplasia differentially expressed (CRNDE) plays an oncogenic role in OS cell lines, and CRNDE can act as a carcinogen by regulating Notch1 signaling and the EMT in OS. Overall, lncRNAs mainly promote the occurrence and development of OS by regulating the proliferation, migration, invasion and EMT of OS cells.

The interaction between lncRNAs and miRNAs promotes the occurrence and development of OS. miRNAs, which have a maximum length of 200 nucleotides, are the most well-known and well-studied non-coding RNAs. Since these molecules appear to play an important role in cellular biology, further investigations are necessary to elucidate their true functions (27).

Jiang et al (28), found that the expression of differentiation antagonizing non-protein coding RNA was increased in OS cells, mediated cancer resistance, enhanced AXL invasion and metastasis by competitively binding with miRNA-33a-5p, and targeting AXL degradation by miRNA-33a-5p via the PI3K/AKT pathway. Wang et al (29), also demonstrated that DANCR could induce the expression of miRNA-335-5p and miRNA-1972, thereby promoting ROCK1-mediated proliferation and transfer through competing endogenous RNA (ceRNA) networks, and thus the development of OS. Ma et al (30), found that UCA1 could act in the ceRNA network of miRNA-582 to positively regulate the expression of CREB1, thereby enhancing the EMT through the PI3K/AKT/mTOR pathway mediated by CREB1, and promoting invasion and metastasis of OS cells. Meanwhile, Liao et al (31) demonstrated that small nucleolar RNA host gene 16 might negatively regulate the expression of miRNA-98-5p. This regulation could effectively reverse the inhibitory effects of miRNA-98-5p on the proliferation, migration, invasion, cell cycle and apoptosis of OS cells. Another report showed that distal-less homeobox 6-AS1 could inhibit the proliferation and metastasis of OS cells by targeting the miRNA-641/HOXA9 signaling pathway and acting as a ceRNA (32). Sun et al (33), found that MALAT1 could regulate the proliferation and metastasis of OS cells by competitively binding with miRNA-34a-5p and miRNA-449a/b. Deng et al (34), showed that lncRNA-small nucleolar RNA host gene 1 (SNHG1) plays an oncogenic role in OS. By activating ROCK1, the PI3K/AKT pathway and the EMT, IncRNA-SNHG1 can downregulate the expression of miRNA-101-3p and promote the proliferation, migration and invasion of cancer cells. Wang et al (35), also confirmed that SNHG1, acting as an endogenous sponge, inhibits the activity of miRNA-326 by increasing the expression of its target gene Nhb1. Dai et al (36), confirmed that OIP5-AS1 acts as a miRNA-223 sponge to trigger CDK4 expression, thus promoting OS tumorigenesis. Li et al (37), demonstrated that TUG1 could accelerate the proliferation, migration, and invasion of OS cells by competitive diffusion of miRNA-219a-5p, leading to the upregulation of PIK3CA and activation of AKT signaling. Another study showed that TUG1, as a ceRNA of miRNA-132-3p, promoted SOX4 expression and inhibited the expression of miRNA-132-3p, leading to increased proliferation and decreased apoptosis of OS cells (38). Moreover, Wang et al (39) found that HOXA-AS2 can promote OS proliferation, migration, invasion and EMT transformation by regulating the expression of miRNA-520c-3p. Deng et al (40), demonstrated that SNHG7 inhibits the growth of tumor suppressor
miRNA-34a and upregulates its target gene, which could induce cell proliferation, cell cycle arrest and apoptosis. Gu et al (41), revealed that LINC00858 regulates the OS phenotype by acting as a ceRNA of miRNA-139 to enhance CDK14 expression. Li et al (42), found that actin filament-associated protein 1-AS1 promoted the proliferation and invasion of OS cells by inhibiting miRNA-4695-5p and activating Tcf4-β-catenin signaling. Xia et al (43) confirmed that inhibition of CAT104 could significantly inhibit the proliferation, migration and invasion of OS cells by regulating the expression of miR-381 and the downstream ZEB1, JNK, and Wnt/β-catenin pathways. Xia et al (44) showed that X inactive specific transcript (XIST) was upregulated in OS tissues and cells. XIST affected the proliferation, invasion and EMT of OS cells by regulating miRNA-195-5p/Yes-associated protein signaling. Zhao et al (45) showed that the lncRNA HIF2PUT could inhibit the proliferation and migration of OS cells, and the self-renewal of OS stem cells, by upregulating HIF-2α. Zhao et al (50) showed that upregulation of EPIC1 could promote ubiquitin-mediated degradation of myocyte-specific enhancer factor 2, an oncogene important in the development of OS. Therefore, EPIC1 can effectively inhibit the occurrence and progression of OS. Chen et al (51) showed that RAB11B-AS1 expression was negatively correlated with RAB11B expression, and thus, RAB11B-AS1 could significantly inhibit the occurrence and development of OS. The results of Qu et al (52) showed that IncRNA WW domain containing oxidoreductase (WWOX)-AS1 inhibited the proliferation, migration and invasion of OS cells. The overall survival rate of the high WWOX-AS1 group was higher compared with...
the low WWOX-AS1 group. Therefore, WWOX-AS1 may be associated with the occurrence and development of OS. Furthermore, the molecular mechanism underlying the inhibition of OS by WWOX-AS1 is associated with genes activated by RUNX2. Moreover, Zhao and Ma (53) found that TH19 expression affected the migration and invasion of OS cells by activating the NF-κB pathway. Zhang et al (54), showed that metastasis associated lung adenocarcinoma transcript 1 (MALAT1) inhibited the occurrence and progression of OS by enhancing the expression of angiogenic factors, such as vascular endothelial growth factor A and fibroblast growth factor 2, via positive regulation of the MALAT1/mTOR/hypoxia-inducible factor-1α pathway. Zhang et al (55) and Sun et al (56) found that MEG3 could inhibit the growth and metastasis of OS cells by inhibiting the Notch and TGF-β signaling pathways. Overall, lncRNAs directly inhibit the occurrence and development of OS by regulating the proliferation, angiogenesis, and metastasis of OS cells.

The interaction between lncRNAs and miRNAs inhibits the occurrence and development of OS. Guo et al (57) found that the lncRNA steroid receptor RNA activator 1 plays an anti-tumor role in OS, via the sponge miRNA-208a, since it decreases cell migration, invasion and proliferation, and promotes apoptosis. Fei et al (58) demonstrated that fer-1 like family member 4 inhibits the proliferation, colony formation, migration and invasion of OS cells by regulating the miRNA-18a-5p/PTEN pathway. Han et al (59) showed that lncRNA-p21 decreased the proliferation of OS cells in vivo and in vitro, by inhibiting the expression of miRNA-130b, thus enhancing the anti-tumor effects of PTEN/pAKT. Yang et al (60) showed that the expression of lncRNA-neuroblastoma associated transcript 1 (NBAT1) is downregulated in OS tissues and cell lines. The downregulated expression of NBAT1 in OS is closely associated with the clinical stage, lymph node metastasis, and prognosis. In addition, NBAT1 was shown to inhibit OS tumor growth and metastasis in vivo by binding miRNA-21. Overall, lncRNAs and miRNAs may inhibit the occurrence and development of OS, by acting as a ceRNA.

5. The role of lncRNAs in OS resistance

At present, the treatment of OS is primarily based on chemotherapy following surgical excision of lesions. In recent decades, with the overall improvement in human health and the development of clinical imaging technology, lesions in some patients with OS are detected early and surgery can be performed before metastasis occurs. However, most patients still require chemotherapy, which contributes to the rapid development of resistance. Chemotherapy resistance of OS is the primary reason for treatment failure at present; determining the intrinsic mechanism of resistance has become an important avenue of research. In addition to their role in the occurrence and development of OS, lncRNAs have also been shown to mediate OS resistance (Table I).

Sun et al (61), demonstrated that the lncRNA plasmacytoma variant translocation 1 (PVT1) could enhance the resistance of OS to gemcitabine by directly targeting and downregulating activation of the c-MET/P3K/AKT pathway by miRNA-152. These results demonstrated that PVT1 not only promotes the occurrence and development of OS, but also enhances the resistance of patients to conventional chemotherapy drugs. Qi et al (62), found that knockdown of the lncRNA KCNQ1OT1 inhibited the proliferation, migration and invasion of OS cells, and upregulated potassium voltage-gated channel subfamily Q member 1 through DNA methyltransferase 1, to promote apoptosis and chemosensitivity to cisplatin (DDP). Therefore, KCNQ1OT1 may be an important promoter of the occurrence, development and chemotherapy resistance of OS. Zhou et al (63), demonstrated that TUG1 also promoted DDP resistance and inhibited DDP-induced cytotoxicity and apoptosis of Saos-2/DDP and MG-63/DDP cells. Song et al (64), showed that the interaction protein 5 (OIP5)-AS1 silencing led to the accumulation of miR-340-5p and thus inhibited mRNA translation, decreased the protein expression of lysophosphatidic acid acyltransferase β (LPAATβ), and inactivated the PI3K/AKT/mTOR signaling, resulting in decreased cisplatin resistance in OS. In conclusion, OIP5-AS1 induced LPAATβ/PI3K/AKT/mTOR signaling by mutagenizing miRNA-340-5p, resulting in cisplatin resistance in OS. Li and
Zhou et al. (66), demonstrated that SNHG12 could enhance OS resistance to doxorubicin (DXR) by inhibiting the expression of miRNA-320a and promoting the expression of MCL1. Knockdown of MCL1 could enhance the sensitivity of OS cells to DXR. In addition, the upregulation of MCL1 could attenuate the sensitivity to DXR induced by the knockdown of mimic RNA-320a and SNHG12. Zhang et al. (67), showed that forkhead box C2 (FOXC2)-AS1, and in particular its FOXC2-overlapping region, exerted these functions by forming RNA-RNA double strands with FOXC2, further increasing the RNA and protein levels of FOXC2 and promoting the expression of ATP binding cassette subfamily B member 1 (ABCB1), a classical multi-drug resistance gene, ultimately resulting in OS resistance to doxorubicin. Han and Shi (68), revealed that lung cancer associated transcript 1 enhances OS resistance to methotrexate by modulating the miRNA-200c ABCB1 pathway. A study by Li et al. (69), showed that HOXA distal transcript antisense RNA, which is overexpressed in OS, plays an important role in OS proliferation, accelerating cell cycle progression and inducing chemoresistance via the Wnt/β-catenin pathway. Therefore, the drug resistance of OS is one of the most important problems in the clinical treatment of OS. Different lncRNAs play an important role in the chemoresistance of OS, which are expected to be a breakthrough point to solve this problem.

Resveratrol is a natural antitoxin that has previously been reported to have selective anti-tumor effects on a variety of tumor cells, including OS. Hu et al. (70), showed that taurine up-regulated 1 (TUG1) was abnormally upregulated in adriamycin-resistant OS cells. Resveratrol can inhibit the proliferation, and promote the apoptosis, of drug-resistant OS cells by inhibiting AKT signaling mediated by TUG1.

6. Summary and prospects

As described in this review, there is ample evidence to support the view that lncRNAs play an important role in the occurrence, growth, invasion, metastasis and drug resistance of OS. Furthermore, it is apparent that different members of the lncRNA family play different roles in OS. Therefore, at present, lncRNAs cannot be defined as cancer initiators or anticancer agents in OS. This will require an understanding of the common mechanisms of lncRNA regulation through exploring the single regulatory roles of different lncRNAs in detail, and determining their associations and mechanism of internal feedback regulation. In this way, important laboratory results can be translated into clinically feasible treatments.

However, it is also important to recognize that current research on the role of lncRNAs in OS is still at the exploratory stage, and there is insufficient evidence to support its use for clinical applications. Nevertheless, it is believed that the current experimental results support lncRNAs as future biomarkers and therapeutic targets in the diagnosis and prognosis of OS.

lncRNAs are used as biomarkers for early diagnosis of OS. lncRNAs play an important regulatory role in OS tumorigenesis, tumor cell proliferation, invasion, migration, apoptosis and angiogenesis. lncRNAs can be secreted and circulated in bodily fluids. As lncRNAs secreted in the circulation are resistant to RNAse, PCR could be used to clinically detect the presence of lncRNAs. Recent reports have indicated lncRNAs as good candidates for tumor markers with high specificity, sensitivity and non-invasive characteristics (71,72).

It is believed that the detection of lncRNAs using readily available clinical specimens, such as blood and articular puncture fluid, could revolutionize the early diagnosis of OS. If early diagnosis of OS can be made, the efficacy of early clinical treatments will be improved.

lncRNAs serve as a molecular target for OS biotherapy. Cancer treatment based on biological targeting technology has been gradually accepted and promoted by clinicians. This type of precise cancer treatment, which shows good therapeutic effects and fewer side effects, represents an important breakthrough. lncRNAs can be targeted using small interfering RNA, antisense oligonucleotides, ribozymes, aptamers and miRNAs; these methods have long been used to target important cancer-associated genes, and are at different stages of clinical trials (73,74). Overall, lncRNAs, which regulate the development of OS, may be a molecular target for OS biotherapies.

Acknowledgements

Not applicable.

Funding

This study was financially supported by the Chinese Medicine Administration Research Project of Gansu province (grant no. GZK-2019-46).

Availability of data and materials

Not applicable.

Authors' contributions

YZ and YP conceived the review. YZ, ZL, and JW wrote the manuscript and revised the manuscript for important intellectual content. All authors have read and approved the final manuscript.

Ethics approval and consent to participate

Not applicable.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.
References
1. Mirabello L, Troisi RJ and Savage SA: Osteosarcoma incidence and survival rates from 1973 to 2004: Data from the surveillance, epidemiology, and end results program. Cancer 115: 1531-1543, 2009.
2. Meyers PA, Heller G, Healey JH, Huvos AG, Applewhite A, Kastner U, Flege S, Kempp-Bielack B, Blumenstein B, Jakschik B, Wang D, Weight L, et al: Expression profiling of long noncoding RNAs associated with vasculogenic mimicry in osteosarcoma. J Cell Biochem 120: 12473-12488, 2019.
3. Li Y, Ehrlich J, Zhang X, Goyal A, Su D, Liu Y, Xiao L, et al: Molecular mechanisms of long non-coding RNAs-mediated cancer metastasis. Genes Chromosomes Cancer 58: 200-207, 2019.
4. Akhade VS, Pal D and Kanduri C: Long non-coding RNA: Genome organization and mechanism of action. Adv Exp Med Biol 1008: 47-74, 2017.
5. Deans C and Maggert KA: What do we mean, ‘epigenetic’? Genes (Baltimore) 99: 887-896, 2015.
6. Chen Z, Gao Y, Yao L, Liu Y, Huang L, Yan Z, Zhao W, Zhu P and Weng H: LncFZD6 initiates Wnt/β-catenin and liver TIC self-renewal through BRG1-mediated FZD6 transcriptional activation. Oncogene 37: 3098-3112, 2018.
7. Deng J, Mueller N and Yu X: Long noncoding RNA LATS2. Biomed Pharmacother 109: 788-797, 2019.
8. Peng Z, Liu C and Wu M: New insights into long noncoding RNAs and their roles in glioma. Mol Cancer 17: 61, 2018.
9. Luo Z, Xiao L, Li J, Dong B and Wang C: Integrative analysis reveals driver long non-coding RNAs in osteosarcoma. Medicine (Baltimore) 98: e14302, 2019.
10. Ren K, Ni Y, Li X, Wang C, Chang Q, Li Y, Gao Z, Wu S, Shi X, Song J, et al: Expression profiling of long noncoding RNAs associated with vasculogenic mimicry in osteosarcoma. J Cell Biochem 120: 12473-12488, 2019.
11. Li Y, Ehrlich J, Zhang X, Goyal A, Su D, Liu Y, Xiao L, et al: Molecular mechanisms of long non-coding RNAs-mediated cancer metastasis. Genes Chromosomes Cancer 58: 200-207, 2019.
12. Akhade VS, Pal D and Kanduri C: Long non-coding RNA: Genome organization and mechanism of action. Adv Exp Med Biol 1008: 47-74, 2017.
13. Deans C and Maggert KA: What do we mean, ‘epigenetic’? Genes (Baltimore) 99: 887-896, 2015.
14. Chen Z, Gao Y, Yao L, Liu Y, Huang L, Yan Z, Zhao W, Zhu P and Weng H: LncFZD6 initiates Wnt/β-catenin and liver TIC self-renewal through BRG1-mediated FZD6 transcriptional activation. Oncogene 37: 3098-3112, 2018.
15. Peng Z, Liu C and Wu M: New insights into long noncoding RNAs and their roles in glioma. Mol Cancer 17: 61, 2018.
16. Luo Z, Xiao L, Li J, Dong B and Wang C: Integrative analysis reveals driver long non-coding RNAs in osteosarcoma. Medicine (Baltimore) 98: e14302, 2019.
17. Ren K, Ni Y, Li X, Wang C, Chang Q, Li Y, Gao Z, Wu S, Shi X, Song J, et al: Expression profiling of long noncoding RNAs associated with vasculogenic mimicry in osteosarcoma. J Cell Biochem 120: 12473-12488, 2019.
18. Li Y, Ehrlich J, Zhang X, Goyal A, Su D, Liu Y, Xiao L, et al: Molecular mechanisms of long non-coding RNAs-mediated cancer metastasis. Genes Chromosomes Cancer 58: 200-207, 2019.
42. Li R, Liu S, Li Y, Tang Q, Xie Y and Zhai R: Long noncoding RNA AFAPI-AS1 enhances cell proliferation and invasion in osteosarcoma through regulating miR-4695-5p/TCF4/β-catenin signaling. Mol Med Rep 18: 1616-1622, 2018.

43. Xia B, Wang L, Feng L, Tian B, Tan Y and Du B: Knockdown of long noncoding RNA CAT104 inhibits the proliferation, migration, and invasion of human osteosarcoma cells by regulating MicroRNA-381. Oncol Res 27: 89-98, 2018.

44. Yang C, Wu K, Wang S and Wei G: Long non-coding RNA XIST promotes osteosarcoma progression by targeting YAP via miR-195-5p. J Cell Biochem 119: 5646-5656, 2018.

45. Zhao J, Zhang C, Gao Z, Wu H, Gu R and Jiang R: Long non-coding RNA ASBEL promotes osteosarcoma cell proliferation, migration, and invasion by regulating microRNA-21. J Cell Biochem 119: 6461-6469, 2018.

46. Zhao J, Zhang C, Gao Z, Wu H, Gu R and Jiang R: Long non-coding RNA MEG3 long non-coding RNA promotes tumorigenesis and metastasis in osteosarcoma by upregulating Notch2 by sponging miR-195-5p. Biochem Biophys Res Commun 495: 1822-1832, 2018.

47. Zhu KP, Ma XL and Zhang CL: LncRNA ODRUL contributes to osteosarcoma stem cells proliferation, migration and invasion by regulating HIF2 expression. Artif Cells Nanomed Biotechnol 47: 1342-1348, 2019.

48. Wang W, Luo P, Guo W, Shi Y, Xu D, Zheng H and Jia L: LncRNA SNHG20 knockdown suppresses the osteosarcoma tumorigenesis through the mitochondrial apoptosis pathway by miR-139/Runx2 axis. Biochem Biophys Res Commun 503: 1927-1933, 2018.

49. Zhao D, Wang S, Chu X and Han D: LncRNA HIF2P2UT inhibits osteosarcoma stem cells proliferation, migration and invasion by regulating HIF2 expression. Artif Cells Nanomed Biotechnol 47: 1342-1348, 2019.

50. Zhao W, Zhang D, Qin P, Zhang J, Cui X, Gao J, Wang J and Li J: Long non-coding RNA EPIC1 inhibits viability and invasion of osteosarcoma cells by promoting MEF2D ubiquitylation. Int J Biol Macromol 128: 566-573, 2019.

51. Chen ZX, Li QC, Liu ZZ, Liang RD and Huang B: Long non-coding RNA RAB11B-AS1 prevents osteosarcoma proliferation via its sense gene RAB11B. Zhonghua Yi Xue Za Zhi 98: 2509-2514, 2018 (In Chinese).

52. Qu G, Ma Z, Tong W and Yang J: LncRNA WWOX-AS1 inhibits the proliferation, migration and invasion of osteosarcoma cells. Mol Med Rep 18: 779-788, 2018.

53. Zhao J and Ma ST: Downregulation of LncRNA H19 inhibits migration and invasion of human osteosarcoma through the NF-κB pathway. Mol Med Rep 17: 7388-7394, 2018.

54. Zhang ZC, Tang C, Dong Y, Zhang J, Yuan T, Tao SC and Li XL: Targeting the long noncoding RNA MALAT1 blocks the pro-angiogenic effects of osteosarcoma and suppresses tumour growth. Int J Biol Sci 13: 1398-1408, 2017.

55. Zhang SZ, Cai L and Li B: MEG3 long non-coding RNA prevents cell growth and metastasis of osteosarcoma. Bratski Listy 118: 632-636, 2017.

56. Sun L, Yang C, Xu J, Feng Y, Wang L and Cui T: Long noncoding RNA EWSAT1 promotes osteosarcoma cell growth and metastasis through suppression of MEG3 expression. DNA Cell Biol 35: 812-818, 2016.

57. Guo W, Jiang H, Li H, Li F, Yu Q, Liu Y, Jiang W and Zhang M: LncRNA-SRA1 suppresses osteosarcoma cell proliferation while promoting cell apoptosis. Technol Cancer Res Treat 18: 153033819841438, 2019.

58. Fei D, Zhang X, Liu J, Tan L, Xing J, Zhao D and Zhang Y: Long noncoding RNA FER1L4 suppresses tumorigenesis by regulating the expression of PTEN targeting miR-186-5p in osteosarcoma. Cell Physiol Biochem 51: 1364-1375, 2018.

59. Han W and Liu J: LncRNA-p21 inhibited the proliferation of osteosarcoma cells via the miR-130b/PTEN/AKT signaling pathway. Biomed Pharmacother 97: 911-918, 2018.

60. Yang C, Wang G, Yang J and Wang L: Long noncoding RNA NBAT1 negatively modulates growth and metastasis of osteosarcoma cells through suppression of miR-24. Am J Cancer Res 7: 2009-2019, 2017.

61. Sun ZY, Xian YK, Zhu HY and Li B: LncRNAVPT1 targets miR-152 to enhance chemoresistance of osteosarcoma to gemcitabine through activating c-MET/PI3K/AKT pathway. Pathol Res Pract 215: 555-563, 2019.

62. Qi X, Yu XJ, Wang XM, Song TN, Zhang J, Guo XZ, Li GJ and Shao M: Knockdown of KCNQOT1 suppresses cell invasion and sensitizes osteosarcoma cells to CDPP by upregulating DNMT1-mediated Kcnq expression. Mol Ther Nucleic Acids 17: 804-818, 2019.

63. Zhou Q, Hu T and Xu Y: Anticancer potential of TUG1 knockdown in cisplatin-resistant osteosarcoma through inhibition of MET/Akt signalling. J Drug Target 28: 204-211, 2020.

64. Song L, Zhou Z, Gan Y, Li P, Xu Y, Zhang Z, Luo F, Xu J, Zhou Q and Dai F: Long noncoding RNA OIP5-AS1 causes cisplatin resistance in osteosarcoma through inducing the LPAAT1/pi3K/AKT/mTOR signaling pathway by sponging the miR-340-5p. J Cell Biochem 120: 9656-9666, 2019.

65. Li G and Zhu Y: Effect of LncRNA ANRIL knockdown on proliferation and cisplatin chemoresistance of osteosarcoma cells in vitro. Pathol Res Pract 215: 931-938, 2019.

66. Zhou B, Li L, Li Y, Sun H and Zeng C: Long noncoding RNA SNHG12 mediates doxorubicin resistance of osteosarcoma via miR-320a/MCL1 axis. Biomed Pharmacother 106: 850-857, 2018.

67. Zhang CL, Zhu KP and Ma XL: Antisense LncRNA FOXC2-AS1 promotes doxorubicin resistance in osteosarcoma by increasing the expression of FOXC2. Cancer Lett 396: 66-75, 2017.

68. Han Z and Shi L: Long non-coding RNA LUCAT11 mediates methotrexate resistance in osteosarcoma via miR-200c/ABCBl axis. Biochem Biophys Res Commun 495: 947-953, 2018.

69. Li Z, Zhao L and Wang Q: Overexpression of long non-coding RNA HOTTIP increases chemoresistance of osteosarcoma cell by activating the Wnt/β-catenin pathway. Am J Transl Res 8: 2385-2393, 2016.

70. Hu T, Fei Z, Su H, Xie R and Chen L: Polydatin inhibits proliferation and promotes apoptosis of doxorubicin-resistant osteosarcoma through LncRNA TUG1-mediated suppression of Akt signaling. Toxicol Appl Pharmacol 371: 55-62, 2019.

71. Yarmishyn AA and Kurochkin IV: Long noncoding RNAs: A potential novel class of cancer biomarkers. Front Genet 6: 145, 2015.

72. Shi T, Gao G and Cao Y: Long noncoding RNAs as novel biomarkers have a promising future in cancer diagnostics. Dis Markers 2016: 9085195, 2016.

73. Begoli R, Sideris N and Giakountis A: LncRNAs as chromatin regulators in cancer: From molecular function to clinical potential. Cancers (Basel) 11: 1524, 2019.

74. Miranda-Castro R, de-Los-Santos-Álvarez N and Lobo-Castañón MJ: Long noncoding RNAs: From genomic junk to rising stars in the early detection of cancer. Anal Bioanal Chem 411: 4265-4275, 2019.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.